Objectives:

Background of BPAL-L
Describe the background of shortened DR-TB regimens and why the BPAL-L regimen was adopted.

Progress Assessment
Evaluate the status of BPAL (Bedaquiline, Pretomanid, Linezolid) implementation efforts, including the adoption rates, accessibility, and utilization of these drugs in the treatment of TB.

Identification of Challenges
Identify and discuss the challenges encountered in the implementation process, such as regulatory hurdles, supply chain issues, healthcare infrastructure limitations, and patient access barriers.

Strategies for Scale-Up
Explore effective strategies for scaling up BPAL implementation, including capacity building for healthcare workers, advocacy for policy changes, strengthening of healthcare systems, and collaboration with stakeholders at local, national, and international levels.

Speakers:

Prof Norbert Ndjeka
Chief Director
Qualifications: MD, DHSM (Wits), MMed (Fam Med) (MED), Dip HIV Man (CMSA), DSc (h.c.)

Dr Francesca Conradie
Principal Investigator
Qualifications: MBBCH

Ms Yulene Kock
Deputy Director

Mr Sajid Sherif
Health Economist and Data Analyst
Qualifications: BCOM Economics Honours